Rare diseases
Investigational molecules
Locations
Recruiting trials first
3 clinical trials in this condition
Bulgaria
France
GermanyIn short
Dermatitis is a widespread skin condition that affects millions of people worldwide, causing discomfort through itching, redness, and inflammation. While there is no single cure, a combination of treatment approaches can help control symptoms, prevent flare-ups, and improve quality of life for those living with this chronic condition.
When someone receives a dermatitis diagnosis, the primary goal of treatment is to bring relief from the often intense itching and visible skin changes that interfere with daily life. Managing this condition effectively means addressing both immediate symptoms during flare-ups and taking preventive measures to keep the skin as healthy as possible between episodes. Treatment plans are highly individual, shaped by the specific type of dermatitis, the severity of symptoms, which areas of the body are affected, and how the condition impacts a person's daily activities and sleep.
The foundation of dermatitis care rests on a combination of daily skin maintenance, avoidance of known triggers, and the use of medications when symptoms worsen. Medical professionals typically recommend a step-by-step approach, starting with gentle skin care routines and moving to stronger treatments only when necessary. This strategy helps minimize potential side effects while maximizing the chances of achieving clear, comfortable skin. Because dermatitis is a long-term condition that tends to come and go, treatment often needs to continue for months or even years.
Beyond just treating the visible rash, effective dermatitis management also considers the emotional and psychological burden of living with a chronic skin condition. Many people with dermatitis experience disrupted sleep due to nighttime itching, feel self-conscious about their appearance, or struggle with stress that can trigger further flare-ups. A comprehensive treatment approach therefore addresses not only the physical symptoms but also the mental and emotional aspects of the disease.
The cornerstone of dermatitis management involves establishing a consistent daily skin care routine. This begins with regular bathing or showering, but not in the way most people might expect. Rather than avoiding water, which many assume would help dry skin, people with dermatitis are actually encouraged to bathe once daily using lukewarm (never hot) water and mild, fragrance-free cleansers or soap substitutes. Hot water can strip away the skin's natural protective oils, making the dryness worse. The duration of bathing should be limited to five to ten minutes to prevent excessive moisture loss from the skin.
After bathing, the skin should be gently patted (not rubbed) dry, leaving it slightly damp. This is the ideal moment to apply moisturizers, also called emollients, which are perhaps the single most important element of dermatitis care. These products work by creating a protective barrier on the skin's surface that locks in moisture and prevents water loss. Emollients come in different forms—ointments, creams, and lotions—with ointments being the most effective for very dry skin because they contain the most oil, though they can feel greasy. Many people need to apply moisturizers two to four times daily or whenever their skin feels dry.
When moisturizers alone cannot control symptoms, topical corticosteroids become the first-line medication for treating dermatitis flare-ups. These are anti-inflammatory medications that come as creams, ointments, or gels and are applied directly to the affected skin. Corticosteroids work by dampening the immune system's overactive response that causes the redness, swelling, and itching. They are available in various strengths, from mild to very potent, and a healthcare provider will prescribe the appropriate strength based on the severity of the dermatitis and where it appears on the body. For example, the skin on the palms and soles of the feet is thicker and can tolerate stronger corticosteroids, while the face and neck require weaker formulations to avoid side effects.
Topical corticosteroids are typically applied once or twice daily to the inflamed areas, usually before moisturizing. When used as directed, they are safe and effective, but overuse or prolonged use of strong corticosteroids can lead to skin thinning or other changes. For this reason, doctors carefully monitor their use and may adjust the strength or frequency of application over time.
Another class of topical medications called calcineurin inhibitors offers an alternative for certain situations. These include tacrolimus and pimecrolimus, which affect the immune system in a different way than corticosteroids. They are particularly useful for treating sensitive areas like the face, eyelids, and neck where long-term use of corticosteroids is not ideal. Calcineurin inhibitors can be used in combination with topical corticosteroids as part of a first-line treatment approach for moderate to severe atopic dermatitis.
For dermatitis that becomes infected—often signaled by weeping, crusting, or pus-filled blisters—antibiotics may be necessary. Bacterial skin infections, commonly caused by the bacterium Staphylococcus aureus, can complicate dermatitis and worsen symptoms. When infection is present, a healthcare provider may prescribe topical or oral antibiotics to clear the infection before resuming standard dermatitis treatment. However, antibiotics are not recommended for routine preventive use, only when there is clear evidence of infection.
Some additional treatments that can help during severe flare-ups include wet wrap therapy, where moisturizing creams or medicated ointments are applied to the skin and then covered with damp bandages, topped with a dry layer. This technique helps the medications penetrate better and provides soothing relief to intensely inflamed skin. Bleach baths, involving diluted bleach added to bathwater, have also been found helpful for some people by reducing bacteria on the skin and decreasing inflammation.
For individuals whose dermatitis does not respond adequately to standard topical treatments, or whose condition is too widespread to treat with creams alone, more intensive therapies may be needed. Phototherapy, also called light therapy, involves exposing the skin to controlled amounts of ultraviolet light under medical supervision. Ultraviolet B (UVB) phototherapy has been studied extensively and is considered a second-line treatment for moderate to severe atopic dermatitis. This treatment requires multiple sessions per week at a medical facility and works by reducing inflammation and slowing the overactive immune response in the skin. It is a safe and effective option for adults when first-line treatments have not provided sufficient relief.
When topical medications and phototherapy are insufficient, systemic treatments—medications taken by mouth or by injection—may be prescribed. Traditional systemic medications for severe dermatitis include immunosuppressants such as ciclosporin, azathioprine, methotrexate, and mycophenolate mofetil. These drugs work throughout the body to dampen the immune system's activity, thereby reducing the inflammation that drives dermatitis. Ciclosporin, in particular, has been used for many years to treat severe atopic dermatitis, though it requires careful monitoring due to potential effects on kidney function and blood pressure.
Oral corticosteroids may provide rapid relief during severe flare-ups, but they are not recommended for long-term use in dermatitis management due to significant side effects and the tendency for symptoms to rebound when the medication is stopped. Medical guidelines specifically advise against using oral steroids as a long-term treatment strategy.
In recent years, significant advances have been made in developing new medications specifically designed to target the biological pathways involved in dermatitis. One of the most important breakthroughs has been the approval of biologic medications. The first biologic approved for atopic dermatitis is dupilumab, an injectable medication that blocks specific proteins (interleukin-4 and interleukin-13) that play key roles in the inflammatory process. Dupilumab is given as an injection every two weeks and has been shown in clinical trials to significantly improve skin clearance and reduce itching in people with moderate to severe atopic dermatitis. Another biologic, tralokinumab, works through a similar mechanism and is also available for severe chronic atopic dermatitis.
Even more recently, a new class of medications called Janus kinase (JAK) inhibitors has entered the treatment landscape. These include upadacitinib, abrocitinib, and baricitinib. JAK inhibitors are taken orally and work by blocking enzymes inside cells that are part of the inflammatory signaling pathway. Clinical trials have demonstrated that these medications can produce rapid and substantial improvements in both the visible signs of dermatitis and the intensity of itching. Upadacitinib, for instance, has been approved for use in severe chronic atopic dermatitis and has shown positive results in Phase III clinical trials, which compare new treatments to existing standard therapies.
Topical versions of these newer medications are also being developed. Crisaborole is a topical medication approved for mild to moderate atopic dermatitis. It works by inhibiting an enzyme called phosphodiesterase 4 (PDE-4), which plays a role in inflammation. Another topical JAK inhibitor, delgocitinib cream, has recently been approved by the U.S. Food and Drug Administration (FDA) as the first treatment specifically for moderate-to-severe chronic hand and foot dermatitis. More topical options, including lebrikizumab, are continuing to be studied in clinical trials.
These newer medications represent a major step forward for people whose dermatitis has not responded to traditional treatments. However, they are currently expensive and may not be accessible to all patients due to cost considerations. Clinical trials for these and other investigational therapies are ongoing in many countries, including in Europe and the United States, and offer opportunities for eligible patients to access cutting-edge treatments while contributing to medical knowledge.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
